Results of a study examining acalabrutinib combined with obinutuzumab for first line treatment of CLL.
Home / Resource Library / Acalabrutinib plus Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
Results of a study examining acalabrutinib combined with obinutuzumab for first line treatment of CLL.